PRINT OUT

News Release

November 08, 2017 Presentation Material for IR Meeting <PDF>
November 06, 2017 Revision of Performance Projection, Dividend of Surplus (Interim Dividend) and Revision of Year-end Dividend Forecast <PDF>
November 06, 2017 Outline of Consolidated Financial Results for the Second Quarter Ended September 30, 2017 <PDF>
October 18, 2017 Revision of Performance Projection <HTML>
August 23, 2017 New Drug Application Filed for Glycoengineered Type II Anti-CD20 Monoclonal Antibody, Obinutuzumab <PDF>
August 09, 2017 Presentation Material for IR Meeting <PDF>
August 09, 2017 Outline of Consolidated Financial Results for the First Quarter Ended June 30, 2017 <PDF>
August 04, 2017 Nippon Shinyaku Co., Ltd. announces final completion of a manufacturing plant for highly active solid formulations <HTML>
July 26, 2017 Nippon Shinyaku Supports Northern Kyushu Heavy Rain Relief Efforts <HTML>
June 01, 2017 Notice Of The 154th Annual General Meeting Of Shareholders <HTML>
May 15, 2017 Presentation Material for IR Meeting <PDF>
May 11, 2017 Outline of Consolidated Financial Results for the Year Ended March 31, 2017 <PDF>
April 25, 2017 Revision of Performance Projection and Dividend Forecast <HTML>
March 30, 2017 Nippon Shinyaku enters into license agreements with Jazz Pharmaceuticals plc for Defitelio® and Vyxeos™ <HTML>
March 24, 2017 Nippon Shinyaku enters into a license agreement with Delta-Fly Pharma on DFP-10917, a therapeutic agent for relapsed/refractory acute myeloid leukemia <HTML>
February 08, 2017 Outline of Consolidated Financial Results for the Third Quarter Ended December 31, 2016 <PDF>
February 08, 2017 Presentation Material for IR Meeting <PDF>
February 01, 2017 FDA Grants Rare Pediatric Disease Designation to NS-065/NCNP-01 for the Treatment of Duchenne Muscular Dystrophy <HTML>
January 19, 2017 First Patient Dosed in Phase 2 Clinical Study of NS-065/NCNP-01 for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping <HTML>
January 16, 2017 FDA Grants Orphan Drug Designation to NS-065/NCNP-01 for the Treatment of Duchenne Muscular Dystrophy <HTML>
get_adobe_reader
page-top